Cargando…
Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review
The purpose of this study was to systematically review the current evidence on apatinib and offer a better understanding of its safety and efficacy in metastatic colorectal cancer (mCRC) patients who have not responded to standard chemotherapies. This systematic review was conducted using research f...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633256/ https://www.ncbi.nlm.nih.gov/pubmed/36348923 http://dx.doi.org/10.7759/cureus.29920 |
_version_ | 1784824222591221760 |
---|---|
author | Khan, Aujala Irfan Mashat, Ghadi D Hazique, Mohammad Khan, Kokab Irfan Ramesh, Prasana Kanagalingam, Suthasenthuran Zargham Ul Haq, FNU Victory Srinivasan, Nishok Khan, Safeera |
author_facet | Khan, Aujala Irfan Mashat, Ghadi D Hazique, Mohammad Khan, Kokab Irfan Ramesh, Prasana Kanagalingam, Suthasenthuran Zargham Ul Haq, FNU Victory Srinivasan, Nishok Khan, Safeera |
author_sort | Khan, Aujala Irfan |
collection | PubMed |
description | The purpose of this study was to systematically review the current evidence on apatinib and offer a better understanding of its safety and efficacy in metastatic colorectal cancer (mCRC) patients who have not responded to standard chemotherapies. This systematic review was conducted using research from the last 10 years (May 30, 2012, to May 30, 2022) and was obtained from the following databases: PubMed, PubMed Central (PMC), ScienceDirect, and Google Scholar. After removing duplicates, screening titles and abstracts, and applying eligibility criteria and quality appraisal, 11 articles were left for this systematic review (one meta-analysis, eight non-randomized studies, and two traditional reviews). Out of the 11 studies, six were on apatinib monotherapy, while three were on apatinib combination therapy. Apatinib has demonstrated efficacy in the monotherapy and combination therapy trials and has exhibited an acceptable safety profile as the adverse events were predominantly graded 1-2 and could be easily managed. Therefore, apatinib is an encouraging candidate for third-line therapy in chemotherapy-refractory mCRC patients. This conclusion should be confirmed and validated by studies with larger, randomized clinical trials to gain better insight and to directly compare the efficacy and safety of apatinib with all current third-line therapies together so that clinicians can easily assess which treatment modality is superior for chemotherapy-refractory mCRC patients. |
format | Online Article Text |
id | pubmed-9633256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-96332562022-11-07 Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review Khan, Aujala Irfan Mashat, Ghadi D Hazique, Mohammad Khan, Kokab Irfan Ramesh, Prasana Kanagalingam, Suthasenthuran Zargham Ul Haq, FNU Victory Srinivasan, Nishok Khan, Safeera Cureus Internal Medicine The purpose of this study was to systematically review the current evidence on apatinib and offer a better understanding of its safety and efficacy in metastatic colorectal cancer (mCRC) patients who have not responded to standard chemotherapies. This systematic review was conducted using research from the last 10 years (May 30, 2012, to May 30, 2022) and was obtained from the following databases: PubMed, PubMed Central (PMC), ScienceDirect, and Google Scholar. After removing duplicates, screening titles and abstracts, and applying eligibility criteria and quality appraisal, 11 articles were left for this systematic review (one meta-analysis, eight non-randomized studies, and two traditional reviews). Out of the 11 studies, six were on apatinib monotherapy, while three were on apatinib combination therapy. Apatinib has demonstrated efficacy in the monotherapy and combination therapy trials and has exhibited an acceptable safety profile as the adverse events were predominantly graded 1-2 and could be easily managed. Therefore, apatinib is an encouraging candidate for third-line therapy in chemotherapy-refractory mCRC patients. This conclusion should be confirmed and validated by studies with larger, randomized clinical trials to gain better insight and to directly compare the efficacy and safety of apatinib with all current third-line therapies together so that clinicians can easily assess which treatment modality is superior for chemotherapy-refractory mCRC patients. Cureus 2022-10-04 /pmc/articles/PMC9633256/ /pubmed/36348923 http://dx.doi.org/10.7759/cureus.29920 Text en Copyright © 2022, Khan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Khan, Aujala Irfan Mashat, Ghadi D Hazique, Mohammad Khan, Kokab Irfan Ramesh, Prasana Kanagalingam, Suthasenthuran Zargham Ul Haq, FNU Victory Srinivasan, Nishok Khan, Safeera Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review |
title | Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review |
title_full | Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review |
title_fullStr | Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review |
title_full_unstemmed | Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review |
title_short | Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review |
title_sort | efficacy and safety of apatinib in the treatment of chemotherapy-refractory metastatic colorectal cancer: a systematic review |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633256/ https://www.ncbi.nlm.nih.gov/pubmed/36348923 http://dx.doi.org/10.7759/cureus.29920 |
work_keys_str_mv | AT khanaujalairfan efficacyandsafetyofapatinibinthetreatmentofchemotherapyrefractorymetastaticcolorectalcancerasystematicreview AT mashatghadid efficacyandsafetyofapatinibinthetreatmentofchemotherapyrefractorymetastaticcolorectalcancerasystematicreview AT haziquemohammad efficacyandsafetyofapatinibinthetreatmentofchemotherapyrefractorymetastaticcolorectalcancerasystematicreview AT khankokabirfan efficacyandsafetyofapatinibinthetreatmentofchemotherapyrefractorymetastaticcolorectalcancerasystematicreview AT rameshprasana efficacyandsafetyofapatinibinthetreatmentofchemotherapyrefractorymetastaticcolorectalcancerasystematicreview AT kanagalingamsuthasenthuran efficacyandsafetyofapatinibinthetreatmentofchemotherapyrefractorymetastaticcolorectalcancerasystematicreview AT zarghamulhaqfnu efficacyandsafetyofapatinibinthetreatmentofchemotherapyrefractorymetastaticcolorectalcancerasystematicreview AT victorysrinivasannishok efficacyandsafetyofapatinibinthetreatmentofchemotherapyrefractorymetastaticcolorectalcancerasystematicreview AT khansafeera efficacyandsafetyofapatinibinthetreatmentofchemotherapyrefractorymetastaticcolorectalcancerasystematicreview |